Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers
27/07/2026 22:10
BRIEF-Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers July 27 (Reuters) - Organogenesis Holdings Inc ORGO.O:
ORGANOGENESIS ANNOUNCES PUBLICATION OF PEER-REVIEWED CLINICAL TRIAL RESULTS DEMONSTRATING CLINICAL BENEFIT OF AFFINITY™ IN THE MOST CHALLENGING AND COMPLEX VENOUS LEG ULCERS
Source text: ID:nGNX9qrg3T
Further company coverage: ORGO.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers